logo

Wockhardt Q2 FY26 Net Profit At ₹82 Crore; Stock Gains Over 8%

By Shishta Dutta | Published at: Nov 3, 2025 05:58 PM IST

Wockhardt Q2 FY26 Net Profit At ₹82 Crore; Stock Gains Over 8%
Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

Mumbai, November 3, 2025 – The shares of Wockhardt Limited jumped 8.78% in Monday trading session, and closed at ₹1,394. The share gained momentum after the company reported a strong turnaround in its second-quarter report for FY26. The share closed higher at ₹112.50 from its previous close of ₹1,281.50 with an intraday high and low of ₹1,433. and ₹1,288.70 and witnessed investors confidence in the company’s financial outcomes.

Key Consolidated Financial Highlights

In Q2 FY26, total income reached ₹803 crore, and profit after tax jumped to ₹82 crore. The numbers show a turnaround in the company’s earnings as it recoverd from a loss of loss of ₹108 crore of first quater of FY26. Operational efficiencies, lower finance costs, and stronger revenue realisation have shifted the financial performance further.

Exceptional Items and US Exit

The company had a charge of ₹97 crore that was exceptional in nature during the period due to the accounting, deconsolidation, and impairment relating to the voluntary liquidation of its US subsidiaries Wockhardt USA LLC and Morton Grove Pharmaceuticals Inc., which filed under Chapter 7 of the US Bankruptcy Code in July 2025.

Board Appointment

The Board has also announced the appointment of Mr Om Prakash Bhatt as an Independent Director for a term of five years, expiring on 2 November 2030. Mr Bhatt is the former Chairman of the State Bank of India and is currently on the boards of Tata Motors Passenger Vehicles, Coforge Limited, and Greenko Energy Holdings.

Founded in 1967, Wockhardt Limited is a multinational pharmaceutical and biotechnology firm that is based in Mumbai. The company operates in India, the UK, and Ireland, as well as in various emerging markets, specializing in anti-infectives, vaccines, and healthcare products based on biotechnology. The company is a component of the Nifty Smallcap 250 index.

REF: https://nsearchives.nseindia.com/corporate/WOCKPHARMA_03112025145112_merged_recognized_newsign.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations

Desktop BannerMobile Banner
Invest Anytime, Anywhere
Play StoreApp Store
Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy